CAJ | 학술논문

目的：研究缺氧诱导因子1α基因(hypoxia-inducible factor-1αgene,HIF1A)多态性与中晚期原发性肝癌预后的相关性。方法收集448例中晚期原发性肝癌行动脉化疗栓塞治疗患者的预后信息,并收集患者外周血5 mL,提取基因组 DNA,检测HIF1A 上3个位点(rs2301113、rs2057482和 rs1957757)的单核苷酸多态性(single nucleotide polymorphism,SNP),多因素的COX 回归,生存曲线和 Log-rank 检验用于分析 SNPs 与肝癌预后的关系。结果在肿瘤最大径<5 cm 的患者中,携带 rs2301113位点突变型(WV+VV)患者的预后显著优于野生型(WW)患者(HR,0.58；95%CI,0.35~0.96；P =0.036)；在单发肿瘤患者中,携带 rs2301113突变型(WV+VV)患者的生存率优于野生型(WW)患者(Log-rank P =0.048)。结论 HIF1A 基因多态性可作为中晚期原发性肝癌行 TACE 治疗的独立预后指标。
목적：연구결양유도인자1α기인(hypoxia-inducible factor-1αgene,HIF1A)다태성여중만기원발성간암예후적상관성。방법수집448례중만기원발성간암행동맥화료전새치료환자적예후신식,병수집환자외주혈5 mL,제취기인조 DNA,검측HIF1A 상3개위점(rs2301113、rs2057482화 rs1957757)적단핵감산다태성(single nucleotide polymorphism,SNP),다인소적COX 회귀,생존곡선화 Log-rank 검험용우분석 SNPs 여간암예후적관계。결과재종류최대경<5 cm 적환자중,휴대 rs2301113위점돌변형(WV+VV)환자적예후현저우우야생형(WW)환자(HR,0.58；95%CI,0.35~0.96；P =0.036)；재단발종류환자중,휴대 rs2301113돌변형(WV+VV)환자적생존솔우우야생형(WW)환자(Log-rank P =0.048)。결론 HIF1A 기인다태성가작위중만기원발성간암행 TACE 치료적독립예후지표。
Objective To assess the association between polymorphisms in HIF1α gene and prognosis of advanced hepatocelluar carcinoma.Methods We collected prognosis data from a cohort of 448 advanced HCC patients treated by transarterial chemoembo-lisation,and used 5ml peripheral blood from patients for extraction DNA.Three SNPs (rs2301 1 13、rs2057482 and rs1 957757 )in HIF1αgene were selected and genotyped.Multivariate Cox proportional hazards model,Kaplan-Meier curve and log-rank test were used for prognosis analyses.Results The variant-containing genotypes (WV+VV)of SNP rs2301 1 13 exhibited a significant associ-ation with a better overall survival in HCC patients who had tumor size smaller than 5 cm (hazard ratio [HR],0.58,95% confidence interval [CI],0.35-0.96,P =0.036).In the patients taken single tumor subgroup,the variant-containing genotypes (WV+VV) of SNP rs2301 1 13 exhibited a significant association with a better overall survival (log-rank P =0.048),comparing to those carrying wild-type genotype.Conclusion Our results suggest that polymorphisms in HIF1αgene may serve as an independent prognosis bio-marker for advanced HCC patient.